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Abstract  
Objectives: To study lung diseases in chronic HCV infection and vice versa and to find 
immunological and/or hereditary interrelating factors.  
Material and Methods: Study included 134 individuals, all were subjected to screening for anti-
HCV antibodies by ELISA, HCV-RNA by real time PCR, pulmonary function tests, quantitative 
assay of interferon gamma and alpha-1- antitrypsin in serum by ELISA and genotyping of alpha-1- 
antitrypsin gene by Light Cycler PCR.  
Results: 76.5% of chronic HCV patients had abnormal PFT (P = 0.03), mainly reduced DLCO and 
reversible airway obstruction, and 41.6% of chest diseased patients were HCV-positive with a 
significant decrease in large and small airways functions. Interferon therapy improved PFT 
parameters. Only 33% of chronic HCV infection affected by chest abnormality responded to 
interferon therapy while 50% of chest free patients did. Serum IFN-γ was higher in HCV and chest 
patients than in control (P=0.02). All serum α1AT deficient patients had M/null genotype.  
Conclusions: A pathogenic role of chronic HCV infection in lung diseases is evident. Interferon 
treatment may reduce chest complications and improve pulmonary functions. However, chest 
affection may reduce the response to interferon treatment. M/null genotype of α1AT gene might 
play a role in chronic HCV infection and chest co-affection.  
 
 
 
 
 
 
 
 
Introduction 
An increasing number of reports have 
suggested that chronic hepatitis C virus (HCV) 
infection is associated with pulmonary disorders. The 
effects of HCV on the lung may present as worsening 
of lung function and impaired response to therapy in 
patients with chronic obstructive pulmonary disease 
(COPD) and asthma. Moreover, chronic HCV infection 
may be associated with the pathogenesis of interstitial 
lung disease [1]. Based on these reports, Kanazawa 
et al [2] have hypothesized that chronic HCV infection 
might trigger inflammation in the lungs, hence, either 
initiating or exacerbating the development of COPD. 
However, data on the prevalence of HCV infection 
among patients with COPD and vice versa is scanty 
[3]. Studies have described a high frequency (close to 
30%) of anti-HCVantibodies in patients with idiopathic 
lung fibrosis (ILF). In some cases, pulmonary 
interstitial involvement may be without evident 
respiratory symptoms [4].  
Secondary effects of HCV infection on 
pulmonary disease are either related to liver cirrhosis 
and portal hypertension or to the autoimmune 
disorders that are occasionally seen in association 
with virus infection. It is well established that chronic 
liver disease can lead to pulmonary derangements 
and mild hypoxemia is a frequent finding in 
approximately one third of patients [5]. The most 
common pulmonary problems occur due to impaired 
clearance of secretions and atelectasis that are 
associated with pleural effusions, ascites, and 
pulmonary edema [6]. Approximately, 10% of patients 
with chronic liver disease acquire unilateral or bilateral 
pleural effusions or "hepatic hydrothorax". In addition, 
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two clinically distinct syndromes that represent a 
continuum of pulmonary vasculopathy have been 
defined in association with liver cirrhosis: 
hepatopulmonary syndrome (HPS), representing 
extreme vasodilatation, and portopulmonary 
hypertension (PPHTN) representing vasoconstriction 
[7].  
Interferon-alpha (IFN-α) is the current 
treatment for chronic HCV infection. However, 
interstitial pneumonitis, bronchiolitis obliterans with 
organizing pneumonia (BOOP), Acute respiratory 
distress syndrome (ARDS), pulmonary hypertension, 
exacerbation of asthma, and sarcoid-like disease 
have been described as complications in HCV 
patients receiving IFN [8]. 
One candidate for a role in pulmonary 
inflammation in HCV patients may be the T 
lymphocyte, in particular the CD8+T cell. During viral 
infections, cytotoxic CD8+T lymphocytes are up-
regulated and activate a cascade of inflammatory 
pathways leading to the release of inflammatory 
mediators [9]. CD8+ cells are also believed to play a 
key role in the development of airway inflammation 
associated with COPD and severe or persistent 
asthma [10].  
One of the most worldwide hereditary 
diseases relating liver and lung affection is the Alpha-
1-antitrypsin (α1AT) deficiency [11]. The unique 
susceptibility of α1AT deficient individuals for 
exposure to chemical and particulate environmental 
agents can result in, both, lung and liver diseases as 
well as other adverse health effects [12,13]. Lung 
manifestations of α1AT deficiency include 
emphysema, chronic bronchitis, COPD, 
bronchiectasis and asthma [14, 15]. While liver 
manifestations include hepatitis, cirrhosis, 
hepatocarcinoma and liver failure [16].  
This work is aiming to study lung disease in 
patients with chronic HCV infection and vice versa 
with a particular attention to response and/or 
complications to medical therapy and to find an 
immunological and/or hereditary factor interrelating 
lung and liver diseases. 
 
Subjects and Methods  
             Our study included 134 adult subjects, 36 
patients with chronic pulmonary diseases (bronchial 
asthma, COPD, bronchiectasis and interstitial lung 
disease), 64 patients with chronic HCV infection 
(positive for both anti-HCV antibodies and HCV-RNA) 
as well as 34 apparently healthy subjects as a control 
group. 
All subjects were compared for risk factors for 
acquisition of HCV infection (blood or blood-products 
transfusion, major surgery, hemodialysis, occupational 
exposure to blood or body fluids, sexual behavior, 
intravenous drug abuse, dental-care procedures, 
shaving at barber shop, tattooing, body piercing, 
professional pedicure/manicure). Exclusion criteria 
included liver cell failure, ascites, pleural effusion and 
working in industrial areas. All participants gave 
written informed consent and the study was approved 
by the ethical committee of the National Research 
Centre.  
All participants were subjected to medical 
history taking, clinical examination, plain chest X-ray 
(postero-anterior view), pre- and post-bronchodilator 
spirometric measurements of FEV1 (forced expiratory 
volume in one second), FEV1/FVC (forced vital 
capacity) and forced expiratory flow (FEF) 25/75% of 
predicted. Bronchodilators were stopped 24 hours 
before pulmonary function tests (PFT). Diffusing 
capacity for Carbon monoxide (DLCO), lung volumes 
(total lung capacity TLC and residual volume RV) 
were assayed in all patients with chronic HCV 
infection (n=64) and in chest disease patients with 
restrictive spirometric function (N=11).  
 
Laboratory measurements  
Screening for anti-HCV antibodies in serum 
was done by Enzyme linked immunosorbent assay 
(ELISA) using DIAKEY, ShinJin Medics Inc. Cat no. 
E031002. HCV-RNA was qualitatively assayed in 
plasma by real time PCR in patients who were 
positive for anti-HCV antibodies. Serum 
concentrations of α1AT and IFN-γ were quantitated by 
ELISA; kits were supplied by Immundiagnostik AG 
and IDlabs Inc Biotechnology, respectively. The 
normal range for IFN-γ is 82-102 pg/ml and for α1AT 
is ˃90 mg/dl. For patients demonstrating α1AT 
deficiency, genotyping of α1AT gene for the two most 
common deficiency alleles S and Z was done using 
LightCycler PCR. 
 
Detection of HCV-RNA by Real Time PCR: 
Viral RNA was extracted from patients' 
plasma using the QIAamp Viral RNA Kit (Qiagen 
Hilden, Germany, Cat no.52904) according to the 
manufacturer's protocol. HCV RNA was detected 
using commercially available Toyobo RNA-direct real 
time PCR kit on SLAN Real Time PCR Detection 
System (LG Lifescience, Korea).  
 
Genotyping of α1-AT PI* S and PI* Z alleles 
by LightCycler PCR 
DNA extraction: Genomic DNA was extracted 
from peripheral blood mononuclear cells using 
QIAamp DNA extraction kit (Qiagen Hilden, Germany, 
Cat no. 51304) according to the manufacturer's 
protocol. The molecular genotype of α1AT gene was 
detected by allele specific probe hybridization on 
LightCycler PCR.  
Genotyping: Two PCR assays, one for each 
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polymorphism, were performed.  
The oligonucleotide sequences for amplifi-
cation in the PI* S genotyping analysis were as 
follows: F 5′-GGTGCCTATGATGAAGCGTTTAGGC-
3′ and R 5′-AGGTGTGGGCAGCTTCTTGGTCA-3′; 
the size of the amplified fragment was 238 bp. 
Hybridization was performed with two oligonucleotide 
probes: 5′-GCACCTGGAAAATGAAC-3′, labelled at 
the 5′ end with a LightCycler red fluorophore LCR 640 
(designed to hybridize over the mutation position) and 
5′-TTCTTCCTGCCTGATGAGGGGAAACTA-3′, labe-
lled with fluorescein at the 3′ end.  
The oligonucleotide sequences for amplifi-
cation in the PI* Z genotyping analysis were F 5′-
GGTGTCCACGTGAGCCTTGC-3′ and R 5′-
AAAAACATGGCCCCAGCAGCT-3′; the size of the 
amplified fragment was 136 bp. Hybridization was 
performed with the 5′-GACCATCGACGAGAAAGGG-
3′ probe, labelled at the 5′ end with a LightCycler red 
fluorophore LCR 640 (designed to hybridize over the 
mutation position) and the 5′-
CTCCAGGCCGTGCATAAGGCTGT-3′ probe labelled 
with fluorescein at the 3′ end.  
The PCR conditions were identical for both 
applications: 3 mM of MgCl2, 4 pmol of each 
hybridization probe, 10 pmol of the two PCR primers, 
2 μl of LightCycler Fast Start DNA Master 
Hybridization probe mix (Roche Diagnostics), and 5 μl 
of DNA sample, in a total volume of 20 μl. PCR 
cycling conditions were as follows: an initial 
denaturation step of 94°C for 7 minutes, followed by 
55 cycles of denaturation at 95°C for 2 seconds, 
annealing at 53°C for 12 seconds, and extension at 
72°C for 15 seconds. After the amplification, melting 
curves were generated by denaturation of the reaction 
at 94°C for 15 seconds, holding the sample at 40°C 
for 20 seconds, and then slowly heating the sample to 
85°C [17]. 
 
Interpretation   
The normal serum level of α1-AT is 
associated with PI MM genotype, intermediate level is 
associated with PI Mnull and PI MZ genotypes, low 
level is associated with PI SZ genotype and finally 
very low level is associated with PI ZZ and PI Znull 
alleles. The current method for molecular genotyping 
is using allele specific hybridization probe that detects 
PI*S or *Z alleles only, thus PI Znull and PI MZ 
individuals will both appear to have one Z and one 
non-Z, non-S allele in molecular genotyping. The 
combination of a very low α1-AT serum protein level 
with genotyping can suggest a PI Znull rather than a 
PI MZ genotype (which would be combined with 
intermediate α1-AT serum protein level) [18].  
 
 
Results 
The study included 134 subjects. They were 
59 (44%) females and 75 (56%) males. Their age 
ranged from 24 to 71 years. According to the results 
of PFT, anti-HCV antibodies by ELISA and HCV-RNA 
by real time PCR; they were divided into 64 patients 
with chronic HCV infection, 36 with chronic chest 
diseases (27 with bronchial asthma, 6 with COPD, 1 
with asthmatic bronchitis, 1 with bronchiectasis and 1 
with interstitial lung disease) and 34 were control 
subjects. Forty-nine patients (76.5%) of chronic HCV 
patients had abnormal PFT and 15 patients (41.6%) of 
chest diseased patients were HCV-positive. 
Demographic and clinical data of the studied subjects 
are shown in Table 1. 
Table 1: Demographic and clinical data of the studied subjects. 
 
Patients with 
Chest disease 
(n=36) 
Patients 
with HCV 
(n=64) 
Control  
(n=34) 
Characteristic 
19/17 16/48 24/10 Sex (F/M) 
45.94 ± 9.34 48.25 ± 9.29 41.41 ± 10.4 Age (years) Mean ± SD  
8 19 0 Smoking 
1 3 0 Family history of HCV 
11 21 0 H/O Major surgery 
18 46 15 H/O dental care procedure 
   Other diseases: 
2 
2 
0 
0 
3 
7 
8 
2 
0 
19 
0 
0 
0 
0 
0 
DM 
HTN 
IHD 
HBV 
Treated Bilharziasis 
 
- 
 
 
 
 
3 
3 
13 
3 
 
 
16 
14 
6 
8 
- 
- 
- 
- 
 
 
- 
 
 
 
 
- 
- 
- 
- 
Treatment 
-Interferon therapy 
     Incomplete 
    complete (48 weeks)   
 Responder 
 Non responder 
-Bronchodilator 
-Inhaled steroids 
-Both 
-Occasional oral steroids 
F = femal; M = male; DM = diabetes mellitus; HTN = hypertension; IHD = ischemic heart 
disease, HBV = hepatitis B virus. 
 
Results of PFTs in different studied groups 
are shown in Table 2. A highly statistical significant 
decrease in the mean value of FEV1 in chest disease 
patients compared to patients with chronic HCV or 
control subjects was observed (P< 0.0001), and in 
chronic HCV patients compared to control subjects as 
well (P< 0.0001). The mean value of FEF25-75% of 
predicted was significantly lower in chest patients 
compared to chronic HCV patients, P <0.05. The 
mean values of FVC% of predicted and SaO2% were 
significantly decreased in chest disease patients and 
chronic HCV patients compared to control group (P 
<0.005 and <0.01, respectively).  
Different chest abnormalities reported in 
patients are shown in Table 3 and Figure 1. PFT 
revealed that 49 cases (76.5%) of chronic HCV 
patients had abnormal PFT (P < 0.05).  
Fifteen cases (41.6%) of chest disease 
patients (n=36) were HCV positive and showed a 
significant decrease in the mean value of FEV1 and 
FEF25-75% of predicted compared to HCV-negative 
patients, P˂0.0001 and P˂0.05, respectively (Table 
4). 
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Table 2: Statistical comparison of post-bronchodilators 
pulmonary function test parameters between the studied 
groups. 
Parameter  
ANOVA 
N Mean SD F-ratio P-value 
FEV1% 
 
Control 34 96.3 11.56 
10.86 < 0.0001 Chest 36 78.6 20.62 
HCV 64 88.6 15.03 
FVC% 
 
Control 34 88.1 6.43 
6.45 <0.005 Chest 36 79.6 17.22 
HCV 64 79.3 11.25 
FEF25-75% 
 
Control 34 94.8 19.47 
3.65 <0.05 Chest 36 80.8 47.29 
HCV 64 100.3 32.84 
TLC% 
 
Control 0   
 
NS Chest 11 82.14 16.76 
HCV 64 86.89 17.74 
RV/TLC% 
Control 0 . . 
2.57 NS Chest 11 42.7 10.56 
HCV 64 37.4 10.13 
DLCO% 
 
Control 0 . . 
1.89 NS Chest 11 69.8 26.49 
HCV 64 78.3 17.32 
DLCO/VA% 
Control 0 . . 
1.82 NS Chest 11 84.5 30.76 
HCV 64 95.0 22.55 
SaO2% 
Control 34 97.5 .93 
4.99 <0.01 Chest 36 96.5 1.76 
HCV 64 97.2 1.24 
FEV1: forced expiratory volume in one second, FVC: forced vital capacity of predicted> 
85%, FEF25-75%: forced expiratory flow of predicted>60%, TLC%: Total lung capacity of 
predicted>60%, RV: residual volume< 33%, DLCO%: Diffusion capacity for Carbon 
monoxide of predicted>85%, VA: alveolar volume, SaO2: oxygen saturation> 95%. *, 
DLCO, TLC, RV were done for all chronic HCV patients and for cases with restrictive 
spirometric functions (n=11) in the chest diseases group. 
 
Twenty patients out of 134 (14.9%) showed 
deficient serum α1AT (<90 mg/dl), of whom, 13 cases 
(65%) had combined chronic HCV infection and chest 
insult. Distribution of α1AT deficiency was as follows: 
16.7% of chest disease patients, 16% of chronic HCV 
patients, 13% of control subjects, and 20.3% of 
combined HCV infection and chest insult patients. 
Genotyping results showed that all had M/null 
genotype (M/ nonS nonZ allele). 
 
Table 3: Interpretation of pulmonary function tests in patient 
groups. 
Chest 
N=36 
HCV 
N=64 
Pulmonary function test 
0 15 Normal functions 
- 16 Reduced diffusing capacity 
5 3 Irreversible airway obstruction and hyperinflation  
2 4 
Irreversible airway obstruction and reduced diffusing 
capacity  hyperinflation 
23 4 Reversible SAW/ LAW obstruction 
3 2 Reversible airway obstruction and hyperinflation 
3 8 
Reversible airway obstruction hyperinflation  and reduced 
diffusing capacity 
2* 4 Reduced lung volume (restriction) 
3* 8 
Reduced lung volume (restriction) and reduced diffusing 
capacity 
5 3 Case with reduced sao2˂95% 
SAW: small airway, LAW: large airway, SaO2: oxygen saturation. *5 cases with reduced 
lung volumes (restriction) in Chest patients group: 2 cases with combined restriction and 
irreversible airway obstruction and 3 cases with combined restriction and reversible airway 
obstruction. 
 
 
Figure 1:  Different chest abnormalities in chronic HCV patients. 
Table 4: Statistical comparison of pulmonary function test 
parameters in chest patients according to the presence or 
absence of HCV infection. 
PFT parameter 
HCV positive HCV negative 
P 
N =15 N = 21 
FEV1% 70.57 ± 19 83.63 ± 20.48 ˂0.0001 
FEF25-75% 63.38 ± 38.47 92.92 ± 51.18 ˂0.05 
TLC% 85.06 ± 17.47 74.33 ± 14.5 NS 
DLCo % 72.86 ± 23.71 62 ± 46.94 NS 
SaO2% 96.8 ± 1.78 96.26 ± 1.76 NS 
Data presented as mean ± SD. FEV1%: forced expiratory volume of predicted, FEF25-
75%: Forced expiratory flow of predicted, TLC%: Total lung capacity of predicted, DLCO%: 
Diffusion capacity for Carbon monoxide of predicted, SaO2: oxygen saturation. 
 
Mean serum level of INFγ was significantly 
higher in chronic HCV patients (95.7 ± 188.5 pg/ml) 
than in both control group (32.6 ± 19.92 pg/ml) and 
chest disease patients (43.6 ± 42.77 pg/ml), P<0.05. 
Also, a non-statistical significant increase was found 
in chronic HCV- chest affected patients (96.8 ± 191.59 
pg/ml) compared to control subjects (32.6 ± 19.92 
pg/ml), chest disease patients (45.8 ± 51.23 pg/ml), 
and chronic HCV-chest free patients (46.3 ± 54.44 
pg/ml), P>0.05.  
Table 5: Statistical comparison of pulmonary function test 
parameters in HCV patients with abnormal PFT according to 
treatment intake. 
PFT parameter 
Nonspecific 
treatment 
Interferon treatment 
P 
N =33 N =30 
FEV1% 81.43±12.26 85.5±13.86 NS 
FEF25-75% 84.96±28.81 104.47±29.64 ˂0.05 
TLC % 
 
81.88±20.39 85.01±17.21 NS 
DLCO % 
 
70.24±14 76.32±16.25 NS 
SaO2% 
 
97.19±0.87 97.28±1.34 NS 
Data presented as mean ± SD. FEV1%: forced expiratory volume of predicted, FEF25-
75%: Forced expiratory flow of predicted, TLC%: Total lung capacity of predicted, DLCO%: 
Diffusion capacity for Carbon monoxide of predicted, SaO2: oxygen saturation. 
 
Studying the effect of interferon therapy on 
PFT, we found a statistical significant increase in the 
mean value of FEV25-75% of predicted in chronic 
HCV patients with abnormal PFT who received 
interferon therapy compared to patients who did not 
receive interferon (P ˂0.05). Also, mean values of 
FEV1%, TLC%, DLCO% and SaO2% were higher in 
patients who received interferon therapy compared to 
those who did not (Table 5). Regarding the effect of 
chest abnormality on the response to interferon 
therapy, 33% of HCV positive- chest cases responded 
to interferon versus 50% of chest free cases who did 
not. 
 
Discussion 
It is believed that chronic HCV infection may 
contribute to the immune responses modulating the 
pathogenic processes underlying pulmonary disorders 
and, therefore, may lead to a wide spectrum of clinical 
presentations [1]. 
We demonstrated a decline in lung functions 
associated with chronic HCV infection. Our results are 
in agreement with Okutan et al. [4] who reported a 
decrease of lower than 80% of the predicted value in 
FVC, FEV1, FEF25-75% and DLCO as well as 
findings of interstitial pulmonary involvement by high-
Clinical Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  44                                                                                                                                                                                                                       http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
resolution computed tomography (HRCT). Similar 
findings were reported by Erturk et al [19] who 
reported that 75% of chronic HCV patients had at 
least one pulmonary alteration as evidenced by 
abnormal PFTs, implicating that pulmonary 
manifestations of chronic HCV are frequently under 
diagnosed.  
Pulmonary function abnormalities in chronic 
liver disease are related to both the degree of 
hepatocellular damage and to the hemodynamic 
changes induced by portosystemic shunt. One of the 
severe complications of chronic liver disease is 
hepatopulmonary syndrome that is defined as a triad 
of liver disease and/or portal hypertension, intrapul-
monary vascular dilatation and hypoxemia, in the 
absence of detectable primary cardiopulmonary 
disease [20, 21].  
About 62% of patients with advanced liver dis-
ease have abnormal pulmonary diffusion capacity with 
a reduced DLCO or DLCO/VA. Abnormal porto-
systemic shunt (increased H/L ratio) is common 
hemodynamic abnormality. Therefore, inverse linear 
correlation between DLCO or DLCO/VA and H/L ratio 
may be an important factor in predicting pulmonary 
complication and meaningful diagnostic and 
prognostic parameters in patients with advanced 
chronic liver disease [22]. In our study, 41.6% of chest 
disease patients were HCV- positive with a significant 
statistical decrease in the mean value of post 
bronchodilator large and small airways compared to 
HCV- negative patients.  
We demonstrated that interferon therapy 
improved the abnormal PFT in chronic HCV patients. 
Contrary to Foster et al [23] who reported frequent 
clinically relevant DLCO declines in chronic HCV 
patients receiving IFNα/ribavirin therapy that persisted 
for ≥6 months post therapy. Meanwhile, Kanazawa et 
al [24] found that interferon therapy induces 
improvement of lung function by inhaled 
corticosteroids in asthmatic patients with chronic HCV 
infection. Also, Kanazawa and Yoshikawa [25] 
reported a significantly lower reversibility with 
salbutamol among HCV-positive asthmatic patients 
who do not respond to interferon therapy than in HCV-
negative patients or interferon responders. In addition, 
the decline in DLCO during a follow-up period of 6 
years was significantly greater in interferon non- 
responders than in HCV-negative patients or 
interferon responders.  
HCV activates a cascade of inflammatory 
pathways leading to the release of inflammatory 
mediators from CD8+ T lymphocytes [9]. Interferon 
gamma INFγ, which was taken in this study as 
indicator of CD8+ activation, was higher in HCV 
patients than in chest or control groups.  
Also, IFN-γ has been shown to be a key 
counter-regulatory anti-fibrotic cytokine down-
regulating the activity of TGF-β (stimulating and 
maintaining the fibrogenic process) and the extent of 
inhibition (or activation) of TGF-β responsive genes 
may be determined by the balance of TGF-β and IFN-
γ signals [29], giving an interpretation of the elevated 
IFN-γ in our HCV patients and explaining the 
interstitial lung affection in such patients manifested 
by restrictive lung functions and reduced diffusing 
capacity. 
Our results indicate that α1AT deficiency and 
M/null genotype of α1AT gene might play a role in 
attraction of chest diseases in chronic HCV infected 
patients. Our results didn't give information regarding 
the effect of α1AT deficiency on the response to 
interferon therapy as all patients who received 
interferon had a normal serum level of α1AT with MM 
genotype. 
In conclusion, a pathogenic role for chronic 
HCV infection in lung diseases is evident. Interferon 
therapy improves pulmonary functions, whereas, 
chest affection may reduce the response to therapy. 
M/null genotype of α1AT gene might play a role in 
HCV infection and chest co-affection. Further 
research to delineate the underlying mechanism is 
needed aiming to find effective therapeutic options 
reducing these complications. 
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